Baseline CD4 + T-cell Count and Cardiovascular Risk Factors Predict the Evolution of Cognitive Performance During 2-Year follow-up in HIV-Infected Patients
Free accessResearch articleFirst published online May, 2015
Baseline CD4 + T-cell Count and Cardiovascular Risk Factors Predict the Evolution of Cognitive Performance During 2-Year follow-up in HIV-Infected Patients
The aim of our study was to better understand the dynamics between cardiovascular risk factors and immunological parameters in the evolution of cognitive performance in HIV+ patients.
Methods
We conducted a prospective longitudinal study, consecutively enrolling asymptomatic HIV+ subjects during routine outpatient visits at two clinical centres. At baseline and after 2 years, all patients underwent a comprehensive neuropsychological battery. Common carotid intima-media thickness (cIMT) was also measured.
Results
A total of 150 patients completed the study (77% males, median age 46 years, 20% with past AIDS-defining events, 95% on cART, 88% with HIV-RNA<50 copies/ml). After a 2-year follow-up, there was no difference in the proportion of patients with cognitive impairment (32% versus 33% at baseline; P=1.00). However, a significantly worse memory performance was observed (z score mean change -0.51, sd 1.05; P=0.001). At multivariate analysis, baseline dyslipidaemia (OR 2.7, 95% CI 1.1, 7.1; P=0.037) showed a significant association with a higher risk of memory impairment at 2-year follow-up, while higher baseline CD4+ T-cell count (OR 0.80 per 100 cells/ml higher; 95% CI 0.66, 0.97; P=0.026) was found to be a protective factor, adjusting for the presence of a memory impairment at baseline. When the analysis was restricted to patients who did not change antiretroviral therapy during the study period (n=109), baseline cIMT (OR 14.6 per 0.1 mm higher; 95% CI 1.1, 189.9; P=0.041) also emerged as an independent risk factor for memory impairment at 2-year follow-up.
Conclusions
Immunological parameters and cardiovascular risk factors are independently associated with the evolution of cognitive status in HIV+ patients.
References
1.
PalellaF.J.Jr., DelaneyK.M., MoormanA.C.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.N Engl J Med1998; 338: 853–860.
2.
McArthurJ.C.HIV dementia: an evolving disease.J Neuroimmunol2004; 157: 3–10.
3.
EttenhoferM.L., FoleyJ., CastellonS.A., HinkinC.H.Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS.Neurology2010; 74: 1217–1222.
4.
CysiqueL.A., BrewB.J.Neuropsychological functioning and antiretroviral treatment in HIV/AIDS: a review.Neuropsychol Rev2009; 19: 169–185.
5.
CiccarelliN., FabbianiM., Di GiambenedettoS.Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients.Neurology2011; 76: 1403–1409.
6.
BrewB.J.Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex.AIDS2004; 18Suppl 1: S75–S78.
7.
DeeksS.G.Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy.Top HIV Med2009; 17: 118–123.
8.
ValcourV., ShikumaC., ShiramizuB.Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort.Neurology2004; 63: 822–827.
9.
BeckerJ.T., LopezO.L., DewM.A., AizensteinH.J.Prevalence of cognitive disorders differs as a function of age in HIV virus infection.AIDS2004; 18Suppl 1: S11–S18.
10.
CiccarelliN., FabbianiM., BaldoneroE.Effect of aging and human immunodeficiency virus infection on cognitive abilities.J Am Geriatr Soc2012; 60: 2048–2055.
11.
SacktorN., SkolaskyR., SelnesO.A.Neuropsychological test profile differences between young and old human immunodeficiency virus-positive individuals.J Neurovirol2007; 13: 203–209.
12.
KillebrewD.A., TroelstrupD., ValcourV.Discordant plasma and cerebral spinal fluid cytokines/chemokines in relation to HIV-1-associated dementia.Cell Mol Biol (Noisy-le-grand)2005; 51 Suppl: OL745–OL754.
13.
FabbianiM., CiccarelliN., TanaM.Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients.HIV Med2013; 14: 136–144.
14.
GrimaP., FabbianiM., CiccarelliN.Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients.J Infect2012; 65: 439–446.
15.
CiccarelliN., FabbianiM., GrimaP.Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients.Infection2013; 41: 1103–1109.
16.
HaydenK.M., ZandiP.P., LyketsosC.G.Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study.Alzheimer Dis Assoc Disord2006; 20: 93–100.
17.
AnsteyK.J., von SandenC., SalimA., O'KearneyR.Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies.Am J Epidemiol2007; 166: 367–378.
18.
SilbertB.S., ScottD.A., EveredL.A., LewisM.S., MaruffP.T.Preexisting cognitive impairment in patients scheduled for elective coronary artery bypass graft surgery.Anesth Analg2007; 104: 1023–1028.
19.
AnsteyK.J., LipnickiD.M., LowL.F.Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis.Am J Geriatr Psychiatry2008; 16: 343–354.
FedeleF., BrunoN., ManconeM.Cardiovascular risk factors and HIV disease.AIDS Rev2011; 13: 119–129.
22.
OnenN.F., OvertonE.T., SeyfriedW.Aging and HIV infection: a comparison between older HIV-infected persons and the general population.HIV Clin Trials2010; 11: 100–109.
23.
LewdenC., MayT., RosenthalE.Changes in causes of death among adults infected by HIV between 2000 and 2005: The ‘Mortalite 2000 and 2005′ surveys (ANRS EN19 and Mortavic).J Acquir Immune Defic Syndr2008; 48: 590–598.
24.
ValcourV.G., ShikumaC.M., ShiramizuB.T.Diabetes, insulin resistance, and dementia among HIV-1-infected patients.J Acquir Immune Defic Syndr2005; 38: 31–36.
25.
WrightE.J., GrundB., RobertsonK.Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons.Neurology2010; 75: 864–873.
26.
BeckerJ.T., KingsleyL., MullenJ.Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men.Neurology2009; 73: 1292–1299.
27.
GuptaS., KnightA.G., LossoB.Y., IngramD.K., KellerJ.N., Bruce-KellerA.J.Brain injury caused by HIV protease inhibitors: role of lipodystrophy and insulin resistance.Antiviral Res2012; 95: 19–29.
28.
EllisR.J., BadieeJ., VaidaF.CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy.AIDS2011; 25: 1747–1751.
29.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.Circulation2002; 106: 3143–3421.
30.
LetendreS., FitzSimonsC., EllisR.Correlates of CSF viral loads in 1221 volunteers of the CHARTER Cohort. 17th Conference on Retroviruses and Opportunistic Infections. 16–19 February 2010, San Francisco, CA, USA. Abstract 172.
31.
CiccarelliN., FabbianiM., ColafigliM.Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia.Antivir Ther2013; 18: 153–160.
32.
AntinoriA., LorenzinP., GiancolaM.L.Antiretroviral CNS Penetration Effectiveness (CPE) 2010 ranking predicts CSF viral suppression only in patients with undetectable HIV-1 RNA in plasma.18th Conference on Retrovirus and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract 426.
33.
BartelsC., WegrzynM., WiedlA., AckermannV., EhrenreichH.Practice effects in healthy adults: a longitudinal study on frequent repetitive cognitive testing.BMC Neurosci2010; 11: 118.
34.
AntinoriA., ArendtG., BeckerJ.T.Updated research nosology for HIV-associated neurocognitive disorders.Neurology2007; 69: 1789–1799.
35.
SteinJ.H., KorcarzC.E., HurstR.T.Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine.J Am Soc Echocardiogr2008; 21: 93–111.
36.
HeatonR.K., FranklinD.R., EllisR.J.HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors.J Neurovirol2011; 17: 3–16.
37.
CysiqueL.A., MaruffP., BrewB.J.Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts.J Neurovirol2004; 10: 350–357.
38.
CysiqueL.A., MaruffP., BrewB.J.Antiretroviral therapy in HIV infection: are neurologically active drugs important?Arch Neurol2004; 61: 1699–1704.
39.
RobertsonK.R., NakasujjaN., WongM.Pattern of neuropsychological performance among HIV positive patients in Uganda.BMC Neurol2007; 7: 8.
40.
CysiqueL.A., BrewB.J.Prevalence of non-confounded HIV-associated neurocognitive impairment in the context of plasma HIV RNA suppression.J Neurovirol2011; 17: 176–183.
41.
HeatonR.K., CliffordD.B., FranklinD.R.HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study.Neurology2010; 75: 2087–2096.
42.
GarveyL., SurendrakumarV., WinstonA.Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy.HIV Clin Trials2011; 12: 333–338.
43.
CysiqueL.A., MoffatK., MooreD.M.HIV, vascular and aging injuries in the brain of clinically stable HIV-infected adults: a (1)H MRS study.PLoS ONE2013; 8: e61738.
BesserL.M., GillD.P., MonsellS.E.Body mass index, weight change, and clinical progression in mild cognitive impairment and Alzheimer disease.Alzheimer Dis Assoc Disord2014; 28: 36–43.
46.
BandaruV.V., MielkeM.M., SacktorN.A lipid storagelike disorder contributes to cognitive decline in HIV-infected subjects.Neurology2013; 81: 1492–1499.
47.
HullM.W., LimaV.D., HoggR.S., HarriganP.R., MontanerJ.S.Epidemiology of treatment failure: a focus on recent trends.Curr Opin HIV AIDS2009; 4: 467–473.
